Pipeline

July 16, 2018

Company	Drug/Device	Medical Condition	Status
OncoNano Medicine	ONM-100 intraoperative imaging agent	tumor acidosis for the detection of solid tumors	Phase I trial initiated enrolling subjects in The Netherlands
BELLUS Health Inc.	BLU-5937	chronic cough	Phase I trial initiated enrolling 90 subjects in the U.S.
Aeromics, Inc.	AER-271	cerebral edema	Phase I trial initiated enrolling 78 healthy subjects in the U.S.
Tetra Discovery Partners	BPN14770	Fragile X Syndrome	Phase II trial initiated enrolling 30 adult male subjects, ages 18-45 years, in the U.S.
BioSight Ltd.	BST-236	Newly-diagnosed Acute Myeloid Leukemia (AML) patients, either de novo or secondary to myelodys-plastic disorder (MDS) who are unfit for standard chemotherapy due to its severe toxicity	Phase IIb trial initiated enrolling subjects in 25 medical centers in the U.S. and Israel
Vidac Pharma	VDA-1102	Actinic Keratosis (AK)	Phase IIb trial initiated enrolling 150 subjects in the U.S.
Citius Pharmaceuticals, Inc.	Mino-Lok therapy in combination with systemic antibiotics	Catheter Related Bloodstream Infections (CRBSIs)	Phase III trial initiated enrolling 700 subjects in the U.S.
Kolon TissueGene, Inc.	Invossa	knee osteoarthritis (OA)	Phase III trial initiated enrolling 1,020 subjects in the U.S.
Recursion	REC-994	cerebral cavernous malformation (CCM)	IND clearance granted by the FDA
Adagene, Inc.	ADG-106	advanced solid tumors and non-Hodgkin lymphoma	IND clearance granted by the FDA
Bausch + Lomb	Loteprednol etabonate ophthalmic gel	management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate	NDA approval granted by the FDA
Zebra Medical Vision	Coronary Calcium Scoring algorithm	coronary artery disease (CAD)	510(k) clearance granted by the FDA
OCULOCARE medical Inc.	Alleye	mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD)	510(k) clearance granted by the FDA
Eagle Pharmaceuticals, Inc.	BENDEKA (bendamustine hydrochloride injection, or bendamustine HCI)	chronic lymphocytic leukemia	Orphan Drug Exclusivity (ODE) granted by the FDA
OBI Pharma Inc.	OBI-3424	Treatment of Hepatocellular Carcinoma (HCC)	Orphan Drug Designation granted by the FDA
US WorldMeds, LLC	LUCEMYRA (lofexidine) tablets	First non-opioid medication indicated for mitigation of opioid with-drawal symptoms to facilitate abrupt opioid discontinuation in adults	Approval granted by the FDA